AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Netspot fda1/7/2024 None Orange Book exclusivity data (new drug applications) Formulation strengthįOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS. Other drugs that have the same active ingredients (e.g. It is based on fluocinonide and gallium ga 68 dotatate (the active ingredients of Vanos and Netspot, respectively), and Vanos and Netspot (the brand names). None Orange Book patent data (new drug applications) Netspot (132 reports) How the study uses the data The study uses data from the FDA. Jubilant DraxImage receives FDA approval for 12-Hour shelf-life for DRAXIMAGE MAA. None FDA Adverse Event Reporting System (Male)Īcid dissociation constants calculated using MoKa v3.0.0 by Jubilant Radiopharma, approved for use with NETSPOT in Canada. The FDA has approved Netspot (Somakit-TATE) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric. A radioactive diagnostic agent used for POSITRON EMISSION TOMOGRAPHY (PET) imaging of SOMATOSTATIN RECEPTOR positive neuroendocrine tumors and malignant abdominal paraganglioma.ĪDVANCED ACCELERATOR APPLICATIONS USA INCįDA Adverse Event Reporting System (Female)
0 Comments
Read More
Leave a Reply. |